



ML-7 (hydrochloride)

Catalog No: tcsc0850



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

110448-33-4

Formula:

 $C_{15}H_{18}CIIN_2O_2S$

Pathway:

Cytoskeleton

Target:

Myosin

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 43 mg/mL (94.98 mM)

Observed Molecular Weight:

452.74

Product Description

ML-7 hydrochloride is a naphthalene sulphonamide derivative, potently inhibits **MLCK** (IC_{50} =300 nM) and TRPC6 channel (IC_{50} >10 μ M).

IC50 & Target: IC50: 300 nM (MLCK)^[1]

In Vitro: ML-7 hydrochloride inhibits rabbit portal vein $\alpha 1$ -adrenoceptor NSCC with IC of 0.8 μ M $^{[1]}$. The myosin light chain kinase





(MLCK) inhibitor ML-7 hydrochloride (3 μ M and 10 μ M) also attenuates the Dexmedetomidine (DMT)-induced contraction (p[2].

In Vivo: In sham operated animals Evans Blue extravasation is not different between ML-7 hydrochloride and vehicle group (sham+vehicle: 0.26 ± 0.02 OD/g; sham+ML-7: 0.26 ± 0.02 OD/g). After CCI inhibition of MLCK with ML-7 results in a significant lower amount of intracerebral Evans Blue compared to vehicle treated animals (CCI+vehicle: 0.42 ± 0.04 OD/g; CCI+ML-7: 0.35 ± 0.05 OD/g, p=0.048)^[3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!